Medication in Autism Spectrum Disorders What Works and What Doesn t
|
|
- Solomon Richardson
- 8 years ago
- Views:
Transcription
1 Medication in Autism Spectrum Disorders What Works and What Doesn t Dr Paramala Santosh, MBBS, MD, DipNB (Psych), FRCPsych, PhD Head, Centre for Interventional Paediatric Psychopharmacology (CIPP) Great Ormond Street Hospital for Children, London Honorary Reader in Child & Adolescent Psychiatry Institute of Child Health, London & Honorary Senior Lecturer in Child & Adolescent Psychiatry Institute of Psychiatry, London
2 Centre for Interventional Paediatric Psychopharmacology (CIPP) Complex Developmental Neuropsychiatry Clinic: Children or adolescents with complex neuropsychiatric disorders, especially those with combined developmental disorders Childhood Dementias Clinic: Children and adolescents with childhood dementias in the context of genetic or medical disorders (e.g. metabolic disorders such as Hurler s, Hunter s, Sanfilipo syndrome, Gaucher s Disease etc.) Childhood Traumatic Brain Injury Psychopharmacology Clinic: Children and adolescents with Acquired Brain Injury who have behavioural problems are assessed and treated. Complex Paediatric Psychopharmacology Clinic: Children and adolescents who have developed unusual or serious side-effects. Research: Clinical and Translational Research
3 Assessment Process Referral from Neurology / Paediatrics / CAMHS Team Discussed by CIPP Questionnaires sent to Parent, Child, Teachers - Analysed Discussion with MDT and Hypotheses Emergencies Pre-morbid Psychopathology Assessment Current Psychopathology Assessment Current MEDICAL Re-assessment Specific Investigations (Neuropsych; MRI; r/o Medical Illness) Psychiatric Diagnoses TREATMENT
4 Treatment Information Sheets for Medication provided Parents opt in to treatment Medication and lack of evidence base discussed with Parents / Child Medication Stabilisation & Monitoring Reviewed in Clinic and Liaison Emergencies dealt via and phone based discussion Shared Care with local services after discharge where possible
5 Developmental Psychopharmacology
6 TYPES OF PHARMACOLOGICAL APPROACHES Disorder-specific approach ADHD, depression, schizophrenia Symptom-based approach paranoia, agitation, explosive rage, poor sleep, anhedonia, hyperactivity, inattention, obsessions & rituals, aggression, self-injurious behaviour
7 Symptom-Based Approach Symptoms that are likely to respond to medication hyperactivity, inattention, obsessions, tics, psychosis, impulsivity, labile mood Symptoms that need behavioural modification as well aggression, rituals, self-injury, depression Symptoms that require specific remediation deficits in academic, social or sports domain
8 Drug Action Used To Improve Symptoms Symptoms Noradrenaline Dopamine Serotonin ACh Obsessions +++ Inattention Hyperactivity Memory + ++ Depression Mood Lability
9 Minimum Effective Dose
10 Dose with Minimum Adverse Effects
11 Minimum Effective Dosing Strategy (MEDS) and Enhancement of Response Functional Analysis of problem behaviour Take underlying cause of symptom into account Start with 1/6-1/8 of expected dose and increase by similar increments every 3 to 7 days depending on pharmacokinetics of drug Regular monitoring for side-effects / response Stop increase as soon as side-effect occurs Wait till it resolves before further increase Increase placebo response and improve concordance of family and child to treatment using non-pharmacological approaches
12 Role of Developmental Status on Pharmacological Intervention
13 Response to Stimulants in co-morbid ASD+ADHD, and ADHD Outcome Measures ASD and ADHD (n=61) Pure ADHD (n=113) Clinical Global Impression Improvement very much improved and much improved minimally worse, much worse and very much worse 31 (51%) 71 (63%) 7 (11%) 17 (15%) Efficacy Index (Mean +- SD) Santosh PJ et al, 2006
14 RUPP - MPH Study I 72 subjects with PDD (autistic disorder, Asperger s disorder, or PDD-NOS) with moderate to severe hyperactivity 6 excluded due to inability to tolerate MPH, leaving 59 boys and 7 girls Exclusion of all those with any other comorbid neuropsychiatric disorders that might require alternative clinical management 3 doses of MPH and placebo trial to chose appropriate dose prior to starting study RUPP studies 0.5 effect size, more side-effects
15 MPH - RUPP Study II (Jahromi et al, 2008) 33 children (29 boys and 4 girls) with PDD with mental age of < 9 years, who had data on the observational measures. Mean age of 6.93 years (SD = 1.83; Range = 5 13 years). MPH 3 doses and placebo given for 1 week at a time in double blind fashion. Exclusion from RUPP I due to - lack of observational data (technical difficulty, video camera malfunction, missed visits, or an uncooperative child) had a mental age above the inclusion criteria, - 2 terminated early due to side effects, - 1 due to parent declining participation, incomplete data, technical difficulties with videos, and - 14 did not schedule videotaping.
16 MPH - RUPP Study II (Jahromi et al, 2008) Frequency of Joint Attention Initiations Frequency of Total Responses to Joint Attention placebo best dose low dose placebo low dose Social Communication Behaviors: Two observers, individually coded the JAMES procedure tapes. Frequency of Joint Attention Initiations: coordinated looks, points to share, shows, and verbal joint attention initiations Frequency of Joint Attention Responding Behaviors: following an invitation by the experimenter, and Frequency of Requesting Behaviors: gives, reaches, points to request, and verbal requests.
17 MPH - RUPP Study II (Jahromi et al, 2008) Self-regulation in the Competing Demands task placebo medium dose Proportion of Regulated Affect placebo medium dose high dose Self-Regulation Behaviors Engaging parent: Attempts to engage the parent in interaction or make bids for attention from the parent Social referencing: Looking at the parent s face Distraction: Prolonged or intense attention to, or manipulation of, an object or toy in the room Self-soothing: Self-manipulative behaviors such as thumb-sucking, fingering clothing, or twirling hair Directed fussing: Child expresses distress vocalizations clearly directed at the parent in an attempt to change the parent s behavior Passive disengagement: Child withdraws passively, or sits without focus on any particular object Leave taking: Attempts by the child to leave the room by banging or opening the door, or verbally indicating desire to leave
18 Atomoxetine in ASD+ADHD 16 subjects (Aut - 7/ Asp-7 PDD NOS - 2) 6-16 years Non verbal IQ> mg/kg/day 8 weeks CGI I 12 (75%) responders on hyperactivity (d = 1-1.9) on hyp on ABC (d = ) on irritability, social withdrawal, stereotypy, repetitive speech 13% dropped out decreased weight 16 subjects 5-15 years 7 Aut / 1 Asp / 8 PDD NOS 0.25mg/kg/day and then increase every 4-5 days by 0.25mg/kg/day 1 week washout in between crossover 6 week trial d = 0.9 for hyperactivity / imp; not inattention 9 responded; 4 responded to placebo 7 were true responders 1 required hospitalization for violence Agitation, mood changes, decreased appetite, GI upset, suicidal ideation, psychosis et al, boys 7-17 years 10 weeks Upto 1.2 mg/kg BW 1 good responder, 5 moderate responders in ADHD symptoms Nausea and headaches. 2 dropouts due to side-effects
19 CLONIDINE IN ASD Useful in ASD with ADHD / Tourette s syndrome Improvement in - hyperactivity, impulsivity, oppositional behaviour, socialisation Side-effects - sedation, hypotension, tolerance, fatigue Especially useful in ASD with insomnia (Ming et al, 2008)
20 Medication in ADHD+ASD Poor response to STIMULANT Dose, compliance Change to ATOMOXETINE / RISPERIDONE Dose, compliance Change to CLONIDINE / CBZ / CHOL BT Persistent after treatment? POLYPHARMACY Diagnosis Co-morbidity?
21 Receptor Activity of the Newer Antipsychotics
22 RUPP Risperidone Trial in ASD Open label risperidone responders 8 week DBPCT (101) : 1.5mg/day; aggression, self injury, severe tantrums better, (sedation, weight gain) Effect size d was CGI improvement Irritability Self-injury Tantrums months open label risperidone (63) : improvement continued on Ritvo-Freeman Real Life Rating Scale, decreased sensory motor behaviours, affectual reactions, sensory symptoms, obsessive and ritualistic behaviour, maladaptive behaviour. No change in social relatedness and communication. ( lbs wt gain). Leptin did not predict weight gain. Double blinded discontinuation 8 weeks (n=32) : 62.5% versus 12.5% relapse. (McKrecken et al, 2002; Arnold et al, 2003; RUPP 2005; Martin et al, 2005; Vitiello et al, 2005; McDougle et al, 2005)
23 Parent Training + Risperidone Risperidone and parent training (COMB) Vs Risperidone alone (MED) in severe behavioral problems in ASD. 24-week, randomized, parallel-groups clinical trial (n= 124 children, aged 4 through 13 years). The children were randomized 3:2 to COMB (n = 75) or MED (n = 49). Received Risperidone monotherapy from 0.5 to 3.5 mg/day (with switch to aripiprazole if risperidone was ineffective). Parents in the COMB group (n = 75; 60.5%) received a mean of 10.9 PT sessions. Primary Outcome: COMB was superior to MED on Home Situations Questionnaire (HSQ) [effect size = 0.34]. Secondary Outcome: groups did not differ on CGI-I scores at endpoint; COMB showed significantly more reductions on ABC - Irritability, Stereotypic Behavior, and Hyperactivity/Noncompliance subscales. Final mean dose for MED was 2.26 mg/day (0.071 mg/kg), compared with 1.98 mg/day for COMB (0.066 mg/kg). Medication plus PT resulted in greater reduction of serious maladaptive behavior than MED in children with ASDs, with a lower risperidone dose. (Aman et al, 2009)
24 Aripiprazole in ASD 98 subjects Autism and irritability (tantrums, aggression, selfinjurious behavior, or a combination of these). Flexibly dosed aripiprazole (target dosage: 5, 10, or 15 mg/day) or placebo. Aripiprazole demonstrated significantly greater global improvements than placebo, from week 1 through week 8. Discontinuation rates % for aripiprazole, 5.9% for placebo. Extrapyramidal symptoms % for aripiprazole and 8.0% for placebo. Weight gain kg aripiprazole, 0.8 kg placebo at week 8. N=218, Autism with irritability (tantrums, aggression, selfinjurious behavior, or a combination of these). Randomized 1:1:1:1 to aripiprazole (5, 10, or 15 mg/day) or placebo. All aripiprazole doses produced greater improvement than placebo in mean CGI improvement and mean ABC Irritability subscale scores. Discontinuation rates : placebo 7.7%, aripiprazole 9.4% to 13.6%. Two serious adverse events: presyncope (5 mg/day) and aggression (10 mg/day). At week 8, mean weight change was : placebo +0.3 kg, aripiprazole +1.3 to 1.5 kg. Sedation was common.
25 Metabolic Syndrome Weight gain, hyperlipidemia, hyperglycaemia, insulin resistance, hypertension Weight Gain High risk - clozapine, olanzapine, risperidone Moderate risk quetiapine Low risk - amisulpiride, ziprasidone, aripiprazole Baseline and follow-up fasting cholesterol, lipids, glucose, insulin, LFT, TFT, U&Es, prolactin, FBC is warranted
26 ASD + ODD Modified CBT - Parent training with modification Affect recognition / misattribution due to social skills Add Risperidone Competence, suitability Dose, compliance BT with little C Persistent after treatment? POLYPHARMACY Diagnosis Co-morbidity?
27 Serotonergic Drugs in ASD Tryptophan depletion in ASD symptoms worsened Fluvoxamine improved mood, speech, social relatedness, repetitive behaviours, aggression, stereotypies (McDougle et al, 1996) SSRIs no better than placebo for repetitive behaviour in ASD (Williams et al, 2010) Fluoxetine in severe depression Sertraline / fluoxetine in severe Anxiety and OCD Behavioural activation common
28 Mood Stabilizers in ASD Possible Indications: Labile Affect, Bipolar Disorder, Explosive Rage, Epilepsy,? EEG abnormality SODIUM VALPROATE: The effect of divalproex sodium for irritability/aggression in ASD. N=55, (mean age 9.46+/-2.46, mean nonverbal IQ 63.3+/-23.9). 12-week DBRPCT, efficacy measures were obtained by an independent evaluator blinded to randomization condition and side effects. 62.5% of divalproex subjects vs 9% of placebo subjects were responders (CGIirritability OR: 16.7) and the ABC-Irritability subscale. There was a trend for responders to have higher valproate blood levels compared with nonresponders. Larger sample follow-up studies are warranted. LAMOTRIGINE, CARBAMAZEPINE ATYPICAL ANTIPSYCHOTICS
29 NALTREXONE IN ASD Initial open trials showed some positive results Double-blind placebo controlled trials show it is no better than placebo Possible improvements in - self-injury and hyperactivity Side-effects - mild / transient, stereotypies worse
30 Oxytocin in ASD Deficits in the ability to recognize the emotions of others are central to ASD. In a double-blind, randomized, placebo-controlled, crossover design, oxytocin nasal spray (18 or 24 IU) or a placebo was administered to 16 male youth aged 12 to 19 who were diagnosed with Autistic or Asperger's Disorder. Participants then completed the Reading the Mind in the Eyes Task, a widely used and reliable test of emotion recognition. In comparison with placebo, oxytocin administration (low and high doses) improved performance on the Reading the Mind in the Eyes Task. This study provides the first evidence that oxytocin nasal spray may improve emotion recognition in young people diagnosed with autism spectrum disorders. (Guastella et al, 2009)
31 Pharmacological Preparation for Medical or Surgical Interventions in ASD / LD Subjects with ASD find medical investigations (eg.mri), minor surgical procedures difficult. May necessitate a General Anaesthetic. Often leads to late intervention Mild - Oral Midazolam Moderate to severely affected - Oral Ketamine Routine IV fluids, antiemesis prophylaxis, and removal of IV cannula before return to ward also help.
32 Case with ASD + Comorbidity HYPERACTIVITY restless, fidgity, on the go IMPULSIVITY- frequently disrupts class, blurts out, shouts INATTENTION distractible, flits from task to task SOCIAL INTERACTION - aloof, little empathy, imaginative play COMMUNICATION - Little social talk, pronominal reversal REPETITIVE/ CIRCUMSCRIBED - maps, capitals of cities, whiz at maths, cognitive rigidity CHALLENGING BEHAVIOUR verbal, property, person, self-injury SLEEP PROBLEM
33 5 Methylphenidate 30mg 4 Severity Hyperactivity Inattention Impulsivity Labile Mood Aggression Appetite Cognitive Rigidity Sleep
34 5 Aripiprazole 2.5mg/day 4 Severity Hyperactivity Inattention Impulsivity Labile Mood Aggression Appetite Cognitive Rigidity Sleep Sleep
35 Concordance and Medication Perceived Side-Effects Symptoms child clinician CON parent QoL Brain Damage Therapeutic Effect in Trials = Drug x Therapeutic Alliance x (Placebo action of Drug / Expectancy effect)
36 CIPP Team CIPP Team Name Dr Paramala Santosh Dr Ruksana Ahmed Dr M. Chiara Colonnelli Dr Otmane El-Mezoued Dr Pushpika Singappuli Dr Laura Roughan Ms Laura McPartlen Mr Michael Woloschin Dr Nagulan Thevarajan Dr Noha Ineusha Ms Nicole Binns Mrs Sandra Poole Position Consultant Child Psychiatrist Consultant Clinical Psychologist Specialty Doctor Specialty Doctor Specialty Doctor Clinical Psychologist Assistant Psychologist Senior Staff Nurse Specialty Registrar Pharmacist Team Administrator and PA Team Administrator
37 Contact Details Dr. Paramala J Santosh Centre for Interventional Paediatric Psychopharmacology (CIPP) Level 4, Frontage Building, Great Ormond Street Hospital for Children, London WC1N 3JH SantoP@gosh.nhs.uk
Comorbid Conditions in Autism Spectrum Illness. David Ermer MD June 13, 2014
Comorbid Conditions in Autism Spectrum Illness David Ermer MD June 13, 2014 Overview Diagnosing comorbidities in autism spectrum illnesses Treatment issues specific to autism spectrum illnesses Treatment
More informationObsessive Compulsive Disorder: a pharmacological treatment approach
Obsessive Compulsive Disorder: a pharmacological treatment approach Professor Alasdair Vance Head, Academic Child Psychiatry Department of Paediatrics University of Melbourne Royal Children s Hospital
More informationAutism Spectrum Disorders and Comorbid Behavioral Health Symptoms
Autism Spectrum Disorders and Comorbid Behavioral Health Symptoms Cynthia King, MD Child and Adolescent Psychiatrist Associate Professor of Psychiatry UNMSOM Psychopharmacologic and Alternative Medicine
More informationRecognizing and Treating Depression in Children and Adolescents.
Recognizing and Treating Depression in Children and Adolescents. KAREN KANDO, MD Division of Child and Adolescent Psychiatry Center for Neuroscience and Behavioral Medicine Phoenix Children s Hospital
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,
More informationADHD PRACTISE PARAMETER. IRSHAAD SHAFFEEULLAH, M.D. A diplomate American Board of CHILD AND ADOLESCENT PSYCHIATRY
ADHD PRACTISE PARAMETER IRSHAAD SHAFFEEULLAH, M.D. A diplomate American Board of CHILD AND ADOLESCENT PSYCHIATRY Similar type of idea Similar document Similar document AACAP document Neurobiological condition
More informationAUTISM SPECTRUM DISORDERS
AUTISM SPECTRUM DISORDERS JAGWINDER SANDHU, MD CHILD, ADOLESCENT AND ADULT PSYCHIATRIST 194 N HARRISON STREET PRINCETON, NJ 08540 PH: 609 751 6607 Staff Psychiatrist Carrier clinic Belle Mead NJ What is
More informationUCLA-NPI/VA PG-2 Child & Adolescent Psychiatry Course 2004-5. Week 3:Attention Deficit Hyperactivity Disorder
UCLA-NPI/VA PG-2 Child & Adolescent Psychiatry Course 2004-5 Week 3:Attention Deficit Hyperactivity Disorder ADHD:Epidemiology Point Prevalence 2-18% M:F>= 2:1 ADHD Symptoms Cognitive (attention) Impulsivity
More informationConjoint Professor Brian Draper
Chronic Serious Mental Illness and Dementia Optimising Quality Care Psychiatry Conjoint Professor Brian Draper Academic Dept. for Old Age Psychiatry, Prince of Wales Hospital, Randwick Cognitive Course
More informationBipolar Disorder. Mania is the word that describes the activated phase of bipolar disorder. The symptoms of mania may include:
Bipolar Disorder What is bipolar disorder? Bipolar disorder, or manic depression, is a medical illness that causes extreme shifts in mood, energy, and functioning. These changes may be subtle or dramatic
More informationDSM-5. Presented by CCESC School Psychologist Interns: Kayla Dodson, M.Ed. Ellen Doll, M.S. Rich Marsicano, Ph.D. Elaine Wahl, Ph.D.
DSM-5 Presented by CCESC School Psychologist Interns: Kayla Dodson, M.Ed. Ellen Doll, M.S. Rich Marsicano, Ph.D. Elaine Wahl, Ph.D. Introduction Lifespan approach to diagnosis Diagnoses occurring in children
More informationPsychopharmacotherapy for Children and Adolescents
TREATMENT GUIDELINES Psychopharmacotherapy for Children and Adolescents Guideline 7 Psychopharmacotherapy for Children and Adolescents Description There are few controlled trials to guide practitioners
More informationMedications Used in the Management of Disruptive Behavior Disorders
The following medication chart is provided as a brief guide to some of the medications used in the management of various behavior disorders, along with their potential benefits and possible side effects.
More informationMEDICATIONS AND TOURETTE S DISORDER: COMBINED PHARMACOTHERAPY AND DRUG INTERACTIONS. Barbara Coffey, M.D., Cheston Berlin, M.D., Alan Naarden, M.D.
MEDICATIONS AND TOURETTE S DISORDER: COMBINED PHARMACOTHERAPY AND DRUG INTERACTIONS Barbara Coffey, M.D., Cheston Berlin, M.D., Alan Naarden, M.D. Introduction Tourette Syndrome (TS) or Tourette s Disorder
More informationTourette syndrome and co-morbidity
Tourette syndrome and co-morbidity Nanette M.M. Mol Debes, M.D., Ph.D. Tourette clinic, Herlev University Hospital, Denmark Outline of presentation Research project Herlev University Hospital Denmark Prevalence
More informationAutism Spectrum Disorder. MAPA Fall Meeting October 9, 2015 Rebecca Klisz-Hulbert, M.D. Assistant Professor
Autism Spectrum Disorder MAPA Fall Meeting October 9, 2015 Rebecca Klisz-Hulbert, M.D. Assistant Professor Learning Objectives Understand the core symptoms that comprise autism spectrum disorder Understand
More informationAutisme Spectrum Disorder & AHDH Mutually Exclusive?!? a Clinical Issue
Autisme Spectrum Disorder & AHDH Mutually Exclusive?!? a Clinical Issue Rutger Jan van der Gaag MD PhD UMC St. Radboud / Karakter UCN University Department Child & Adolescent Psychiatry Nijmegen, the Netherlands
More informationMedication Management of Depressive Disorders in Children and Adolescents. Satya Tata, M.D. Kansas University Medical Center
Medication Management of Depressive Disorders in Children and Adolescents Satya Tata, M.D. Kansas University Medical Center First Line Medications SSRIs Prozac (Fluoxetine): 5-605 mg Zoloft (Sertraline):
More informationin young people Management of depression in primary care Key recommendations: 1 Management
Management of depression in young people in primary care Key recommendations: 1 Management A young person with mild or moderate depression should typically be managed within primary care services A strength-based
More informationBRIEF NOTES ON THE MENTAL HEALTH OF CHILDREN AND ADOLESCENTS
BRIEF NOTES ON THE MENTAL HEALTH OF CHILDREN AND ADOLESCENTS The future of our country depends on the mental health and strength of our young people. However, many children have mental health problems
More informationAntipsychotic drugs are the cornerstone of treatment
Article Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic T. Scott Stroup, M.D.,
More informationDementa Formulary Guidance [v1.0]
Dementa Formulary Guidance [v1.0] 1. Introduction These Guidelines are intended for routine use. However there will be instances where they are not suitable for the patient you are managing, where more
More informationDSM 5 AND DISRUPTIVE MOOD DYSREGULATION DISORDER Gail Fernandez, M.D.
DSM 5 AND DISRUPTIVE MOOD DYSREGULATION DISORDER Gail Fernandez, M.D. GOALS Learn DSM 5 criteria for DMDD Understand the theoretical background of DMDD Discuss background, pathophysiology and treatment
More informationDrugs PSYCHOSIS. Depression. Stress Medical Illness. Mania. Schizophrenia
Drugs Stress Medical Illness PSYCHOSIS Depression Schizophrenia Mania Disorders In preschool children imaginary friends and belief in monsters under the bed is normal (it may be normal in older developmentally
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationDocumentation Requirements ADHD
Documentation Requirements ADHD Attention Deficit Hyperactivity Disorder (ADHD) is considered a neurobiological disability that interferes with a person s ability to sustain attention, focus on a task
More informationAutism Spectrum Disorders and Co-Occurring Mental Health Conditions
Autism Spectrum Disorders and Co-Occurring Mental Health Conditions Sydney Rice, MD, MS University of Arizona LEND Erika Ryst, M.D. University of Nevada LEND October 5, 2015 Overview Children with autism
More informationClinical Audit: Prescribing antipsychotic medication for people with dementia
Clinical Audit: Prescribing antipsychotic medication for people with dementia Trust, team and patient information Q1. Patient's DIS number... Q2. Patient s residence: Home Residential Home Nursing Home
More informationADHD and Autism (and everything else in between) Dr Ankit Mathur Consultant Community Paediatrician
ADHD and Autism (and everything else in between) Dr Ankit Mathur Consultant Community Paediatrician Objectives Community Paediatric service pathways Importance of these conditions Case studies Differential
More informationOverview of Mental Health Medication Trends
America s State of Mind Report is a Medco Health Solutions, Inc. analysis examining trends in the utilization of mental health related medications among the insured population. The research reviewed prescription
More informationIrritability and DSM-5 Disruptive Mood Dysregulation Disorder (DMDD): Correlates, predictors, and outcome in children
Irritability and DSM-5 Disruptive Mood Dysregulation Disorder (DMDD): Correlates, predictors, and outcome in children Ellen Leibenluft, M.D. Chief, Section on Bipolar Spectrum Disorders National Institute
More informationNeuropsychiatry Disorders
Neuropsychiatry Disorders Larry Fisher, Ph.D., ABN UHS Neurobehavioral Systems (Copyright UHS 2009; All rights reserved) For more information: Larry Fisher, Ph.D., ABN UHS Neurobehavioral Systems 12710
More informationATYPICALS ANTIPSYCHOTIC MEDICATIONS
The atypical antipsychotics are a class of drugs that are used to treat a number of behavioral health disorders, including schizophrenia, other psychotic disorders, mood disorders, and behavioral agitation
More informationAntipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers
SUPPLEMENT 1: (Supplementary Material for online publication) Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers About this
More informationFact Sheet 10 DSM-5 and Autism Spectrum Disorder
Fact Sheet 10 DSM-5 and Autism Spectrum Disorder A diagnosis of autism is made on the basis of observed behaviour. There are no blood tests, no single defining symptom and no physical characteristics that
More informationPSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS. Juanaelena Garcia, MD Psychiatry Director Institute for Family Health
PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS Juanaelena Garcia, MD Psychiatry Director Institute for Family Health Learning Objectives Learn basics about the various types of medications that
More informationAlgorithm for Initiating Antidepressant Therapy in Depression
Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression
More informationMCPS Special Education Parent Summit
MCPS Special Education Parent Summit May 17, 2014 Rockville High School 2100 Baltimore Road Rockville, MD 20851 When ADHD Is Not ADHD: ADHD Look-Alikes and Co-occurring Disorders David W. Holdefer MCPS
More informationAutistic Disorder Asperger s Disorder Pervasive Developmental Disorder, Not Otherwise Specified (PDD-NOS)
Medical Policy Manual Topic: Applied Behavior Analysis for the Treatment of Autism Spectrum Disorder Date of Origin: January 2012 Section: Behavioral Health Last Reviewed Date: January 2015 Policy No:
More informationPsychiatrists should be aware of the signs of Asperger s Syndrome as they appear in adolescents and adults if diagnostic errors are to be avoided.
INFORMATION SHEET Age Group: Sheet Title: Adults Depression or Mental Health Problems People with Asperger s Syndrome are particularly vulnerable to mental health problems such as anxiety and depression,
More informationThese guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes.
This is a new guideline. These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes. It incorporates NICE clinical
More informationDEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource
E-Resource March, 2015 DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource Depression affects approximately 20% of the general population
More informationLong Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine)
1 of 8 USE OF CHOLINESTERASE (AChE) INHIBITORS The cholinesterase inhibitor anti-dementia drugs are indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer s
More informationAmphetamines Addiction
Introduction Amphetamines, which are classified as stimulants, work by using the dopamine reward system of the brain. When these drugs are used, the user s central nervous system is simulated which causes
More informationDEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE
1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff
More informationAUTISM SPECTRUM DISORDER TREATMENTS
AUTISM SPECTRUM DISORDER TREATMENTS Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage
More informationDEMENTIA EDUCATION & TRAINING PROGRAM
The pharmacological management of aggression in the nursing home requires careful assessment and methodical treatment to assure maximum safety for patients, nursing home residents and staff. Aggressive
More informationADEPT Glossary of Key Terms
ADEPT Glossary of Key Terms A-B-C (Antecedent-Behavior-Consequence) The three-part equation for success in teaching. Antecedents (A) Anything that occurs before a behavior or a skill. When teaching a skill,
More informationSummary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole)
EMA/303592/2015 Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Pharmathen, which details the measures
More informationGuide to Using Psychotropic Medication to Manage Behaviour Problems among Adults with Intellectual Disability
Guide to Using Psychotropic Medication to Manage Behaviour Problems among Adults with Intellectual Disability Technical Document Shoumitro Deb, MBBS, FRCPsych, MD, Clinical Professor of Neuropsychiatry
More informationADHD. & Coexisting Disorders in Children
ADHD & Coexisting Disorders in Children ADHD AND CHILDREN Attention-deficit/hyperactivity disorder (ADHD) is a recognized medical condition that often requires medical intervention. Establishing a diagnosis
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationFor more than 100 years, extremely hyperactive
8 WHAT WE KNOW ADHD Predominantly Inattentive Type For more than 100 years, extremely hyperactive children have been recognized as having behavioral problems. In the 1970s, doctors recognized that those
More information1/23/2014 TOPICS PHARMACOLOGY: UPDATES AND REVIEW. Elizabeth Reeve MD HealthPartners Medical Group Gillette Children s Specialty Heath Care
PHARMACOLOGY: UPDATES AND REVIEW Elizabeth Reeve MD HealthPartners Medical Group Gillette Children s Specialty Heath Care TOPICS General pharmacology concepts when prescribing for children and adults When
More information[KQ 804] FEBRUARY 2007 Sub. Code: 9105
[KQ 804] FEBRUARY 2007 Sub. Code: 9105 (Revised Regulations) Theory : Two hours and forty minutes Q.P. Code: 419105 Maximum : 100 marks Theory : 80 marks M.C.Q. : Twenty minutes M.C.Q. : 20 marks 1. A
More informationUpdate on Treatment of the Dementias
Update on Treatment of the Dementias Mark Pippenger, MD Behavioral Neurology Associate Clinical Professor of Neurology University of Arkansas for Medical Sciences Disclosures I will be discussing off-label
More informationAttention, memory and learning and acquired brain injury. Vicki Anderson. Jamie M. Attention & learning: an information processing model
Attention, memory and learning and acquired brain injury Vicki Anderson Jamie M. Childhood acquired amnesia Attention & learning: an information processing model MANAGEMENT Organising, problem solving
More informationI. The Positive Symptoms...Page 2. The Negative Symptoms...Page 2. Primary Psychiatric Conditions...Page 2
SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SPA PCP Treatment & Referral Guideline Assessment & Treatment of Psychosis Developed March 1, 2003 Revised September 21,
More informationBOARD OF PHARMACY SPECIALITIES 2215 Constitution Avenue, NW Washington, DC 20037-2985 202-429-7591 FAX 202-429-6304 bps@aphanet.org www.bpsweb.
BOARD OF PHARMACY SPECIALITIES 2215 Constitution Avenue, NW Washington, DC 20037-2985 202-429-7591 FAX 202-429-6304 bps@aphanet.org www.bpsweb.org Content Outline for the PSYCHIATRIC PHARMACY SPECIALTY
More informationPsychotic Disorder. Psychosis. Psychoses may be caused by: Examples of Hallucinations and Delusions 12/12/2012
Psychosis Psychotic Disorder Dr Lim Boon Leng Psychiatrist and Medical Director Dr BL Lim Centre For Psychological Wellness Tel: 64796456 Email: info@psywellness.com.sg Web: www.psywellness.com.sg A condition
More informationCrosswalk to DSM-IV-TR
Crosswalk to DSM-IV-TR Note: This Crosswalk includes only those codes most frequently found on existing CDERs. It does not include all of the codes listed in the DSM-IV-TR nor does it include all codes
More informationAntidepressant treatment in adults
Antidepressant treatment in adults A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive and
More informationClinical Practice Guidelines: Attention Deficit/Hyperactivity Disorder
Clinical Practice Guidelines: Attention Deficit/Hyperactivity Disorder AACAP Official Action: OUTLINE OF PRACTICE PARAMETERS FOR THE ASSESSMENT AND TREATMENT OF CHILDREN, ADOLESCENTS, AND ADULTS WITH ADHD
More informationUnderstanding Antipsychotic Medications
Understanding Antipsychotic Medications NARSAD RESEARCH National Alliance for Research on Schizophrenia and Depression 60 Cutter Mill Road, Suite 404 Great Neck, NY 11021 516-829-0091 1-800-829-8289 516-487-6930
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
The European Medicines Agency Evaluation of Medicines for Human Use London, 20 January 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS
More informationAutism Spectrum Disorders Diagnosis. March 9, 2009 LEND Training Program Allison D. Brooks, Ph.D. University of Washington Autism Center
Autism Spectrum Disorders Diagnosis March 9, 2009 LEND Training Program Allison D. Brooks, Ph.D. University of Washington Autism Center Autism Spectrum Disorders Communication Social Restricted/ Repetitive
More informationConduct Disorder: Treatment Recommendations. For Vermont Youth. From the. State Interagency Team
Conduct Disorder: Treatment Recommendations For Vermont Youth From the State Interagency Team By Bill McMains, Medical Director, Vermont DDMHS Alice Maynard, Mental Health Quality Management Chief, Vermont
More information2. The prescribing clinician will register with the designated manufacturer.
Clozapine Management Program Description Magellan of Arizona Pharmacy Program Background: Magellan Health Services of Arizona recognizes the importance of a clozapine program. Clozapine received increased
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationTreating Children with Anxiety and Bipolar Disorder. Ellen Leibenluft, M.D.
Treating Children with Anxiety and Bipolar Disorder Ellen Leibenluft, M.D. Chief, Section on Bipolar Spectrum Disorders Emotion and Development Branch National Institute of Mental Health National Institutes
More informationClinic of Psychiatry, Medical Faculty, Vilnius University, Lithuania 2
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 72 No. 3 pp. 597ñ606, 2015 ISSN 0001-6837 Polish Pharmaceutical Society CLINICAL EXPERIENCE OF LONG-TERM TREATMENT WITH ARIPIPRAZOLE (ABILIFY) IN CHILDREN
More informationAutism Spectrum Disorders. This section was co-authored by Robert Hilt, MD and A.A. Golombek, MD
Autism Spectrum Disorders This section was co-authored by Robert Hilt, MD and A.A. Golombek, MD 48 Considering an Autism Spectrum Disorder? Any Early Red Flags? Not smiling in response to being smiled
More informationPublished 09 September 2013 1. 09 August 2013
aripiprazole 5mg, 10mg, 15mg, 30mg tablets, 10mg, 15mg orodispersible tablets, 1mg/mL oral solution (Abilify ) SMC No. (891/13) Otsuka Pharmaceutical (UK) Ltd 09 August 2013 The Scottish Medicines Consortium
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationRegister of Students with Severe Disabilities
Department of Education Learners first, connected and inspired Register of Students with Severe Disabilities Department of Education Register of Students with Severe Disabilities 1. Eligibility Criteria
More informationSee also www.thiswayup.org.au/clinic for an online treatment course.
Depression What is depression? Depression is one of the common human emotional states. It is common to experience feelings of sadness and tiredness in response to life events, such as losses or disappointments.
More informationMOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines
MOH CLINICL PRCTICE GUIELINES 2/2008 Prescribing of Benzodiazepines College of Family Physicians, Singapore cademy of Medicine, Singapore Executive summary of recommendations etails of recommendations
More informationSymptoms of mania can include: 3
Bipolar Disorder This factsheet gives information on bipolar disorder. It explains the symptoms of bipolar disorder, treatments and ways to manage symptoms. It also covers what treatment the National Institute
More informationMedications for bipolar disorder
Medications for bipolar disorder Findings from Australian National Survey of Mental Health and Wellbeing (Mitchell et al, 2004) In 12 months, only one-third saw a mental health professional 40% received
More informationNICE Clinical guideline 23
NICE Clinical guideline 23 Depression Management of depression in primary and secondary care Consultation on amendments to recommendations concerning venlafaxine On 31 May 2006 the MHRA issued revised
More information`çããçå=jéåí~ä= aáëçêçéêëw=^åñáéíó=~åç= aééêéëëáçå. aêk=`=f=lâçåü~ jéçáå~ä=aáêéåíçê lñäé~ë=kep=cçìåç~íáçå=qêìëí=
`çããçå=jéåí~ä= aáëçêçéêëw=^åñáéíó=~åç= aééêéëëáçå aêk=`=f=lâçåü~ jéçáå~ä=aáêéåíçê lñäé~ë=kep=cçìåç~íáçå=qêìëí= Overview: Common Mental What are they? Disorders Why are they important? How do they affect
More informationA Guide for Enabling Scouts with Cognitive Impairments
A Guide for Enabling Scouts with Cognitive Impairments What cognitive impairments are discussed in this manual? Autism Spectrum Disorder Attention Deficit Hyper Activity Disorder Depression Down Syndrome
More informationDepression in the Elderly: Recognition, Diagnosis, and Treatment
Depression in the Elderly: Recognition, Diagnosis, and Treatment LOUIS A. CANCELLARO, PhD, MD, EFAC Psych Professor Emeritus and Interim Chair ETSU Department of Psychiatry & Behavioral Sciences Diagnosis
More informationClinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72
Attention deficit hyperactivity disorder: diagnosis and management Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72 NICE 2008. All rights reserved. Last updated February 2016 Contents
More informationChapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of
Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of antipsychotic agents Identify common adverse effects
More informationPSYCHOTROPIC MEDICATIONS
PSYCHOTROPIC MEDICATIONS 644.3 Bipolar Disorder This Instructor s Guide contains: Brief Description, Objectives, Discussion Questions, Pretest, Post-test, Answer Keys and Glossary for this program, Psychotropic
More informationTrends in Prescribing of Antipsychotic Drugs in General Practice in England (Chart 1) 2.0. Other second generation antipsychotics (SGA)
Antipsychotic drugs Antipsychotics can be broadly classified into first generation antipsychotics (FGAs, formerly known as typical antipsychotics) and second generation antipsychotics (SGAs, formerly known
More informationDEPRESSION CODING FACT SHEET FOR PRIMARY CARE CLINICIANS
DEPRESSION CODING FACT SHEET FOR PRIMARY CARE CLINICIANS Current Procedural Terminology (CPT ) (Procedure) Codes Initial assessment usually involves a lot of time determining the differential diagnosis,
More informationDepression in children and young people. Identification and management in primary, community and secondary care
NICE guideline May 2005 Issue date: September 2005 Depression in children and young people Identification and management in primary, community and secondary care Clinical Guideline 28 Developed by the
More informationADHD AND ANXIETY AND DEPRESSION AN OVERVIEW
ADHD AND ANXIETY AND DEPRESSION AN OVERVIEW A/Professor Alasdair Vance Head, Academic Child Psychiatry Department of Paediatrics University of Melbourne Telephone: 9345 4666 Facsimile: 9345 6002 Email:
More informationMemory, Behaviour, Emotional and Personality Changes after a Brain Injury
Memory, Behaviour, Emotional and Personality Changes after a Brain Injury The consequences of a brain injury on any individual, family or relationship are far reaching. A brain injury not only impacts
More informationDepre r s e sio i n o i n i a dults Yousuf Al Farsi
Depression in adults Yousuf Al Farsi Objectives 1. Aetiology 2. Classification 3. Major depression 4. Screening 5. Differential diagnosis 6. Treatment approach 7. When to refer 8. Complication 9. Prognosis
More informationDepression Assessment & Treatment
Depressive Symptoms? Administer depression screening tool: PSC Depression Assessment & Treatment Yes Positive screen Safety Screen (see Appendix): Administer every visit Neglect/Abuse? Thoughts of hurting
More informationPOST-TRAUMATIC STRESS DISORDER PTSD Diagnostic Criteria PTSD Detection and Diagnosis PC-PTSD Screen PCL-C Screen PTSD Treatment Treatment Algorithm
E-Resource March, 2014 POST-TRAUMATIC STRESS DISORDER PTSD Diagnostic Criteria PTSD Detection and Diagnosis PC-PTSD Screen PCL-C Screen PTSD Treatment Treatment Algorithm Post-traumatic Stress Disorder
More informationHow To Ensure That Children With Angegea Are Treated Properly
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL SECOND-GENERATION ANTIPSYCHOTIC DRUG USE AMONG MEDICAID-ENROLLED CHILDREN: QUALITY-OF-CARE CONCERNS Daniel R. Levinson Inspector General
More informationRecognition and Treatment of Depression in Parkinson s Disease
Recognition and Treatment of Depression in Parkinson s Disease Web Ross VA Pacific Islands Health Care System What is depression? Depression is a serious medical condition that affects a person s feelings,
More informationOCD & Anxiety: Helen Blair Simpson, M.D., Ph.D.
OCD & Anxiety: Symptoms, Treatment, & How to Cope Helen Blair Simpson, M.D., Ph.D. Professor of Clinical Psychiatry, Columbia University Director of the Anxiety Disorders Clinic, New York State Psychiatric
More information1AC. All definitions will be contextually defined and the affirmative reserves the right to clarify upon further scrutiny.
Marilyn Elias, USA Today, 05/02/2006 New antipsychotic drugs carry risks for children Nancy Thomas remembers the bad old days when she had to wear long-sleeve clothes to church to cover bite marks all
More informationBehavioral and Pharmacologic Treatment of Aggression in Children With Autism
http://www.cmp.com/ http://www.psychiatrictimes.com/ Behavioral and Pharmacologic Treatment of Aggression in Children With Autism By Craig A. Erickson, M.D., Naomi B. Swiezy, Ph.D., Kimberly A. Stigler,
More informationChronic mental illness in LTCF. Chronic mental illness. Other psychiatric disorders.
Chronic mental illness in LTCF Abhilash K. Desai MD Medical Director Alzheimer s Center of Excellence Chronic mental illness 1. Schizophrenia and Schizoaffective disorder. 2. Bipolar disorder (Type 1 and
More information